Dr. Veda Giri discusses registry evaluating genetic testing in prostate cancerMarch 1st 2023
“The field of germline testing for prostate cancer has expanded significantly; it's really become central in terms of thinking about treatment for men with metastatic prostate cancer,” says Veda Giri, MD.
Dr. Giri and Dr. Loeb discuss prostate cancer genetic testing podcast seriesFebruary 22nd 2023
“We need to leverage these great platforms to put out high-quality information with experts that people can listen to from home or on the go and get the information that they need,” says Stacy Loeb, MD, MSc.
Sacituzumab govitecan shows efficacy in metastatic urothelial cancer after progression on CPIFebruary 17th 2023
“These data support further evaluation of sacituzumab govitecan—alone or in combination—in patients with metastatic urothelial carcinoma who progressed after prior CPI therapy,” says Daniel P. Petrylak, MD.
Yale urology professor named medical director, Smilow Cancer Hospital Care Center at Greenwich HospitalJanuary 20th 2023
An associate professor of Urology at Yale School of Medicine, Dr. Kenney specializes in treating genitourinary cancers, with a particular focus on kidney cancers.
What new guideline or presentation from the 2022 AUA Annual Meeting will have the biggest impact on urologists?November 15th 2022
"We increasingly see the evolving role of ‘precision medicine’ in urology, using genetic and genomic testing to guide [management] for a variety of diseases, particularly bladder and prostate cancer," says 1 urologist.
Yale professors create new drug that could combat prostate cancerOctober 12th 2022
A Yale chemist and oncologist collaborated to create a new treatment for prostate cancer that tags specific proteins within the cancerous cells, making it easier for the body’s natural mechanisms to identify and destroy them.
Yale urology chair reflects on first yearSeptember 27th 2022
"I have no doubt we’ll become a destination program. We have a great team. Combined with a few key recruitments, we will be set to take our place on the global stage of urology," says Isaac Y. Kim, MD, PhD, MBA, urology professor and chair, Yale Urology.
For Medicaid-insured patients with cancer, health insurance does not always mean health accessJuly 19th 2022
“We found that Medicaid acceptance differed widely across cancer care facilities," said Michael Leapman, MD, MHS, associate professor of Urology, clinical program leader for the Prostate & Urologic Cancers Program at Yale Cancer Center and Smilow Cancer Hospital.
Dr. Preston Sprenkle discusses the significance of promoting testicular cancer awarenessMay 10th 2022
"Because testicular cancer is most often diagnosed in young men and treatments are very successful, the focus is on minimizing the short- and long-term impacts of treatment," says Sprenkle.
Dr. Petrylak highlights the latest advances in metastatic urothelial cancerMarch 22nd 2022
In discussing treatment determinations, Petrylak noted that for patients with low PD-L1 expression had decreased survival benefits compared with patients treated with chemotherapy in the monotherapy arms of the phase 3 KEYNOTE-361 (NCT02853305) and phase 3 IMVIGOR-130 (NCT02807636) trials.
Encouraging antitumor activity seen with neoadjuvant enfortumab vedotin in patients with cisplatin-ineligible MIBCFebruary 19th 2022
“This first disclosure of data supports the ongoing phase 2 and 3 programs evaluating enfor-tumab vedotin alone or in combination with pembrolizumab in MIBC,” said Daniel P. Petrylak, MD.